2020
DOI: 10.1007/s10295-020-02289-1
|View full text |Cite
|
Sign up to set email alerts
|

Recent advances in the biosynthesis of RiPPs from multicore-containing precursor peptides

Abstract: Ribosomally synthesized and post-translationally modified peptides (RiPPs) compose a large structurally and functionally diverse family of natural products. The biosynthesis system of RiPPs typically involves a precursor peptide comprising of a leader and core motif and nearby processing enzymes that recognize the leader and act on the core for producing modified peptides. Interest in RiPPs has increased substantially in recent years as improvements in genome mining techniques have dramatically improved access… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 17 publications
(12 citation statements)
references
References 128 publications
(15 reference statements)
0
12
0
Order By: Relevance
“…They display a wide array of biological activites, such as inhibition of nucleotide/protein synthesis, metal ion chelation, cell membrane permeation, cell apoptosis regulation, cytokine release modulation, or acting as siderophores. 207,[210][211][212][213][214] Although some of these NRPs are key players in the clinic (e.g. vancomycin), there are still very few AMPs that are currently undergoing preclinical studies or clinical trials, approved by the FDA, or undergoing commercial development.…”
Section: (Non)ribosomally-synthesised Amps and The Current Clinical Landscapementioning
confidence: 99%
“…They display a wide array of biological activites, such as inhibition of nucleotide/protein synthesis, metal ion chelation, cell membrane permeation, cell apoptosis regulation, cytokine release modulation, or acting as siderophores. 207,[210][211][212][213][214] Although some of these NRPs are key players in the clinic (e.g. vancomycin), there are still very few AMPs that are currently undergoing preclinical studies or clinical trials, approved by the FDA, or undergoing commercial development.…”
Section: (Non)ribosomally-synthesised Amps and The Current Clinical Landscapementioning
confidence: 99%
“…Genome mining of RiPP BGCs is revealing the presence of precursor peptides that contain multiple core regions in otherwise unrelated RiPP families as observed previously in the cyanobactins 43 and fungal and plant peptides. 44 Recently, Kim and co-workers have greatly expanded the number of examples of multicore graspetides by directing their searches to BGCs containing ATP-grasp ligases and core regions with Ser/Thr nucleophiles and the receiving Asp/Glu amino acids. 21 Biochemical and mass spectrometric characterization of those BGCs revealed new multicore ω-ester-containing peptides with diverse connectivities or topologies.…”
Section: ■ Discussion and Conclusionmentioning
confidence: 99%
“…Here, we posit that RiPP biosynthetic enzymes present in biosynthetic gene clusters (BGCs) containing multiple substrate peptide-encoding genes will inherently be substrate promiscuous as they need to modify different substrates in their native physiological context. This rationalization is supported by the discovery of broadly substrate-tolerant lanthipeptide synthetases that modify numerous different substrate peptides encoded in cyanobacterial genomes. Also reminiscent are the substrate promiscuous peptide macrocyclases that modify multiple different core regions present in a single substrate peptide for the biosynthesis of cyanobactins, microviridins, and fungal and plant macrocyclic RiPPs . These substrate promiscuous RiPP biosynthetic enzymes can then be used as peptide-modifying biotechnology tools , and also used combinatorically with other RiPP biosynthetic enzymes to build expansive natural product libraries. …”
Section: Introductionmentioning
confidence: 99%